Some of the top trading pics of ICICI Direct which can fetch up to 12-44 per cent returns in the long term.
The market saw an increase for the sixth consecutive day on 9 February. Important indices gained over 1 percent on this day. Here we are giving some of the top trading pics of broking house ICICI Direct which can see returns of 12-44 per cent in the long term.
Sumitomo Chemicals
The current price of this share is around Rs 305. The stock has a buy recommendation target of Rs 360. It can easily see an 18 percent increase. ICICI Direct says that the company’s strategy of changing the product mix will see a good increase in its margins ahead. The company will also get the benefit of further price increase.
Brigade Enterprises
Its current price in this stock is around Rs 285. The stock recommends buying ICICI Direct for a target of Rs 320. The brokerage house believes that upside of 12 per cent can be easily seen. The company will benefit from the jump in commercial and residential property sales. This will help the company to increase its cash as well as reduce its debt.
PNC Infratech
The share price is around Rs 268. This stock recommends ICICI Direct purchase target of Rs 300. ICICIDirect believes that the stock can easily see a growth of 12 per cent. The company has a large number of EPC orders. The company’s balance seat is also very strong. The government will also benefit from the government’s focus on infrasectors.
Somany Ceramics
This stock is around Rs 385. ICICI Direct recommends investment for this 500 rupee target. The brokerage house believes that upside of 29 per cent can be easily seen. For the company, its working capital management and focus strategy on reducing its net debt have been most beneficial. With increasing demand, the company’s margins will also improve. Investors will benefit from it.
Divis Laboratories
The current price of this stock is around Rs 3781.65. ICICI Direct has given a target of Rs 4440 for the stock. The brokerage house believes that it can easily see an upside of 17 per cent in the long term. The company’s results in the third quarter were better than expected on all fronts. Further, the company’s investment plans will see further growth in its business. Along with this, the company will also benefit from the Chine Plus factor which is gaining emphasis all over the world.
Cadila Healthcare
ICICI Direct has a purchase recommendation for a target of Rs 555. Brokerage House’s opinion that the upside of 17% will be easily seen in this stock. The company’s results in the third quarter were as expected. The company has benefited from the reduction in interest cost and reduction in tax rates. The company plans to make inroads in the US in the business of injectables (71 ANDAs have been filed) which will have a good impact in the business of the company. Along with this, the company’s growing move in the biosimilar sector will also benefit.
